Cabaletta Bio, Inc. develops engineered T cell therapies for autoimmune diseases as a late-stage clinical biotechnology company. Its CABA platform includes the CARTA strategy, and its lead investigational therapy, rese-cel (resecabtagene autoleucel), is a fully human CD19-CAR T cell therapy evaluated through the RESET clinical development program across rheumatology, neurology and dermatology.
Recurring company updates cover rese-cel clinical and translational data, trial-program presentations, manufacturing scale-up, and supply arrangements using automated cell-therapy production platforms. News also includes financial results, business updates, conference participation, shareholder voting matters, capital-structure disclosures, and regulatory disclosures tied to Cabaletta Bio’s autoimmune cell-therapy pipeline.
Cabaletta Bio, Inc. (Nasdaq: CABA) presented updated clinical data from its DesCAARTes™ trial at the ASGCT Annual Meeting. The interim data, involving 12 treated subjects across four cohorts, demonstrated a favorable safety profile for DSG3-CAART with no dose-limiting toxicities. Notably, a dose-dependent increase in persistence of DSG3-CAART cells was observed. The trial aims to escalate dosages while assessing the relationship between cell persistence and clinical response in patients with mucosal-dominant pemphigus vulgaris (mPV). The company is planning additional cohorts to augment its research.
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotech company, will have CEO Steven Nichtberger participate in a fireside chat at the H.C. Wainwright Global Investment Conference on May 24, 2022, at 11:00 a.m. ET in Miami, FL. This event will highlight the company's focus on developing targeted cell therapies for autoimmune diseases. Interested individuals can access a live webcast on the company's website, with replays available for 30 days after the event.
Cabaletta Bio (CABA) reported Q1 2022 financial results, revealing a net loss of $12.9 million, or $0.45 per share. Research and development expenses surged to $9.2 million, driven by ongoing clinical trials. The cash balance fell to $109.2 million from $122.2 million, expected to support operations until Q3 2023. Key advancements include progress in the DesCAARTes™ trial for mucosal pemphigus vulgaris and plans to initiate a first-in-human trial for MuSK-CAART in myasthenia gravis, following FDA Fast Track Designation.
Cabaletta Bio (Nasdaq: CABA) announced the presentation of data from its lead programs, DSG3-CAART and MuSK-CAART, at various scientific meetings in May 2022. The DSG3-CAART trial is currently in Phase 1, targeting mucosal pemphigus vulgaris. Presentations will showcase early cohort data and further characterization of DSG3-CAART cells. The MuSK-CAART program will include preclinical studies on myasthenia gravis. Key events are at the American Society of Gene & Cell Therapy and Society for Investigative Dermatology meetings.
Cabaletta Bio, a clinical-stage biotechnology company (Nasdaq: CABA), announced that Gwendolyn Binder, Ph.D., will present a pre-recorded session at the 21st Annual Needham Virtual Healthcare Conference.
This presentation will be available on-demand starting April 12, 2022, at 3:45 p.m. ET, and can be accessed via the company’s website, with replays available for 30 days. Cabaletta Bio focuses on developing targeted T cell therapies for autoimmune diseases, with a growing pipeline that includes treatments for conditions like pemphigus vulgaris and myasthenia gravis.
Cabaletta Bio, Inc. (CABA) reported its fourth quarter and full year 2021 financial results and provided a business update. The company ended 2021 with $122.2 million in cash, funding operations through Q3 2023. Significant advancements include the DesCAARTes™ trial, showing positive early results in cohorts, and the MuSK-CAART IND application cleared by the FDA with Fast Track Designation granted. Upcoming data presentations are scheduled for mid-2022, which are anticipated to provide insights into ongoing trials.
Cabaletta Bio has received Fast Track Designation from the FDA for its MuSK-CAART therapy, aimed at improving daily living and muscle strength in patients with MuSK antibody-positive myasthenia gravis (MG). The IND application was cleared, enabling a first-in-human clinical trial set to start in 2022 with approximately 20 patients. The trial will include dose escalation and cohort expansion. The therapy targets autoantibodies specifically, addressing a critical unmet need as current treatments have significant limitations.
Cabaletta Bio, a clinical-stage biotechnology company focused on targeted cell therapies for autoimmune diseases, announced that CEO Steven Nichtberger will join the Neuromuscular corporate panel at the Cowen Virtual 42nd Annual Health Care Conference on March 7, 2022, at 9:10 a.m. ET.
A live webcast will be accessible on the company's website, with replays available for 30 days. Cabaletta Bio's innovative CABA platform aims to develop therapies for conditions like pemphigus vulgaris and myasthenia gravis, positioning the company at the forefront of biotechnological advancements in autoimmune treatment.
Cabaletta Bio, a clinical-stage biotechnology company, has announced the promotions of Gwendolyn Binder, Ph.D. to President of Science and Technology and Arun Das, M.D. to Chief Business Officer. Dr. Binder, previously Executive Vice President, has a strong background in engineered T cell therapy, while Dr. Das, formerly Executive Director of New Product Planning, has significant experience in business development. Both leaders will report to CEO Steven Nichtberger, emphasizing strategic contributions to enhance the company's mission to develop treatments for B cell-mediated autoimmune diseases.
Cabaletta Bio, a clinical-stage biotechnology company (Nasdaq: CABA), announced that CEO Steven Nichtberger, M.D. will present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 9:00 a.m. ET. A live webcast will be available on their website, with a replay accessible for 90 days.
The company focuses on engineered T cell therapies for B cell-mediated autoimmune diseases. Their lead candidate, DSG3-CAART, is in the DesCAARTes™ Phase 1 clinical trial for pemphigus vulgaris and has received Fast Track Designation from the FDA.